Innoviva (INVA) Long-Term Investments (2012 - 2026)
Innoviva posted quarterly Long-Term Investments of $413.1 million for Q1 2026, up 41.9% year-on-year from $291.1 million in Q1 2025, and up 2.12% on a QoQ basis from $404.5 million in Q4 2025.
Innoviva (INVA) has 11 years of Long-Term Investments data on file, last reported at $413.1 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Investments rose 41.9% year-over-year to $413.1 million; the trailing twelve-month figure through Mar 2026 stood at $413.1 million (up 41.9% YoY), and the FY2025 full-year result was $404.5 million, up 18.39% from the prior year.
- Long-Term Investments for Q1 2026 stood at $413.1 million, up from $404.5 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $544.4 million in Q1 2022 and bottomed at $291.1 million in Q1 2025.
- The 5-year median for Long-Term Investments is $413.1 million (2026), against an average of $412.0 million.
- The widest annual swing landed in 2025, when Long-Term Investments plunged 38.91%; it then soared 41.9% in 2026.
- A 5-year view of Long-Term Investments shows it stood at $363.9 million in 2022, then increased by 22.14% to $444.4 million in 2023, then slipped by 23.12% to $341.7 million in 2024, then grew by 18.39% to $404.5 million in 2025, then grew by 2.12% to $413.1 million in 2026.
- The last three Long-Term Investments figures came in at $413.1 million (Q1 2026), $404.5 million (Q4 2025), and $343.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 413.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 413.08 Mn |
| Dec 31, 2025 | 404.50 Mn |
| Sep 30, 2025 | 343.79 Mn |
| Jun 30, 2025 | 297.28 Mn |
| Mar 31, 2025 | 291.10 Mn |
| Dec 31, 2024 | 341.66 Mn |
| Sep 30, 2024 | 434.17 Mn |
| Jun 30, 2024 | 444.66 Mn |
| Mar 31, 2024 | 476.55 Mn |
| Dec 31, 2023 | 444.43 Mn |
| Sep 30, 2023 | 422.49 Mn |
| Jun 30, 2023 | 397.94 Mn |
| Mar 31, 2023 | 400.89 Mn |
| Dec 31, 2022 | 363.86 Mn |
| Sep 30, 2022 | 489.11 Mn |
| Jun 30, 2022 | 494.10 Mn |
| Mar 31, 2022 | 544.44 Mn |
| Dec 31, 2021 | 483.85 Mn |
| Sep 30, 2021 | 507.12 Mn |
| Jun 30, 2021 | 473.68 Mn |
| Mar 31, 2021 | 519.33 Mn |
| Dec 31, 2020 | 438.26 Mn |
| Sep 30, 2020 | 111.75 Mn |
| Jun 30, 2020 | 128.61 Mn |
| Mar 31, 2020 | 46.92 Mn |
| Mar 31, 2015 | 3.93 Mn |
| Dec 31, 2014 | 42.86 Mn |
| Sep 30, 2014 | 47.75 Mn |
| Jun 30, 2014 | 34.35 Mn |
| Mar 31, 2014 | 59.83 Mn |
| Dec 31, 2013 | 55.37 Mn |
| Sep 30, 2013 | 88.33 Mn |
| Jun 30, 2013 | 90.31 Mn |
| Mar 31, 2013 | 99.34 Mn |
| Dec 31, 2012 | 95.19 Mn |
| Sep 30, 2012 | 88.96 Mn |
| Jun 30, 2012 | 83.21 Mn |